Evidence map›Paper›PMID 23355270›Full record

ArticleAngewandte Chemie (International ed. in English)2013

BN/CC isosteric compounds as enzyme inhibitors: N- and B-ethyl-1,2-azaborine inhibit ethylbenzene hydroxylation as nonconvertible substrate analogues.

Daniel H Knack, Jonathan L Marshall, Gregory P Harlow, Agnieszka Dudzik, Maciej Szaleniec, Shih-Yuan Liu, Johann Heider

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 140 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The aromatic Claisen rearrangement of a 1,2-azaborine.Organic & biomolecular chemistry · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Selectivity in the Elaboration of Bicyclic Borazarenes.Advanced synthesis & catalysis · 2021
    Article
  14. Article
  15. Pd-Senphos Catalyzed trans-Selective Cyanoboration of 1,3-Enynes.Angewandte Chemie (International ed. in English) · 2020
    Article
  16. Article
  17. Accessing 1,2-Substituted Cyclobutanes through 1,2-Azaborine Photoisomerization.Angewandte Chemie (International ed. in English) · 2019
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Daniel H KnackLaboratory for Microbial Biochemistry, Philipps University of Marburg, 35043 Marburg, Germany.
Jonathan L Marshall
Gregory P Harlow
Agnieszka Dudzik
Maciej Szaleniec
Shih-Yuan Liu
Johann Heider
University of Oregon · USJerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences · PLPhilipps University of Marburg · DE

Funding

Development of BN Heterocycles for Biomedical ResearchR01GM094541 · NIGMS · UNIVERSITY OF OREGON · PI LIU, SHIH-YUAN · 2010 to 2019
$2.8M
NIGMS NIH HHS R01 GM094541
6 · The paper itself

Abstract

Good substrate gone bad! BN/CC isosterism of ethylbenzene leads to N-ethyl-1,2-azaborine and B-ethyl-1,2-azaborine. In contrast to ethylbenzene, which is the substrate for ethylbenzene dehydrogenase (EbDH), N-ethyl-1,2-azaborine (see scheme; Fc=Ferricenium tetrafluoroborate) and B-ethyl-1,2-azaborine are strong inhibitors of EbDH. Thus, the changes provided by BN/CC isosterism can lead to new biochemical reactivity.

Indexed as

Benzene DerivativesBoron CompoundsEnzyme InhibitorsHydroxylationOxidoreductases1,2-azaborineBenzene DerivativesBoron CompoundsEnzyme Inhibitorsethylbenzeneethylbenzene dehydrogenaseOxidoreductases

Identifiers

PMID23355270
PMCPMC3748812
OpenAlexW2057213036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.